Earnings

Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate

Sep 22, 2026 · 04:06 PM ET· updated 2h ago

Aytu BioPharma (NASDAQ:AYTU) reported quarterly sales of $16.106 million which beat the analyst consensus estimate of $12.276 million by 31.20 percent. This is a 6.42 percent increase over sales of $15.135 million the

Why It Matters

Aytu BioPharma sold more stuff than experts thought it would. When a company beats its sales target, it means the business is doing better than people expected.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AYTU2.28

+0.16 (+7.48%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.